Financial Performance - Q3 2021 revenue reached ¥322,247,927.52, an increase of 37.62% year-over-year[2] - Net profit attributable to shareholders was ¥94,271,234.99, up 76.76% compared to the same period last year[2] - Net profit excluding non-recurring gains and losses for the period was ¥87,962,581.12, reflecting a 94.72% increase year-over-year[2] - Basic earnings per share for Q3 2021 was ¥0.36, up 111.76% from the previous year[3] - Total operating revenue for the first three quarters of 2021 reached ¥856,804,399.15, a 35.7% increase from ¥631,513,285.48 in the same period of 2020[15] - Net profit for the third quarter of 2021 was ¥247,009,521.78, compared to ¥142,479,212.65 in the same quarter of 2020, representing a 73.2% increase[17] - The net profit attributable to shareholders of the parent company for the third quarter of 2021 was ¥248,006,161.31, up from ¥143,556,153.79 in the previous year[19] - Basic earnings per share for the third quarter of 2021 were ¥0.95, compared to ¥0.45 in the same quarter of 2020[19] Cash Flow and Investments - Cash flow from operating activities for the year-to-date period was ¥463,447,574.19, showing a 106.82% increase[3] - The company reported a significant increase in cash flow due to higher sales collections resulting from business growth[7] - The net cash flow from operating activities for the first three quarters of 2021 was CNY 463,447,574.19, a significant increase of 106.7% compared to CNY 224,084,428.91 in the same period of 2020[20] - Total cash inflow from investment activities was CNY 404,057,385.13, up from CNY 331,436,170.51 in the previous year, while cash outflow for investment activities surged to CNY 2,290,934,619.51 from CNY 508,987,148.73[21] - The cash flow from investment activities showed a net outflow of CNY 1,886,877,234.38, compared to a net outflow of CNY 177,550,978.22 in the previous year, indicating increased investment activities[21] - The company’s cash inflow from financing activities was primarily driven by CNY 5,407,415,864.64 received from investments, a significant increase from CNY 32,872,124.88 in the previous year[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,201,780,654.41, a 289.11% increase from the previous year[3] - The total assets of the company as of September 30, 2021, amount to 8,201,780,654.41 RMB, compared to 2,107,821,636.06 RMB at the end of 2020[13] - The total liabilities of the company as of September 30, 2021, are 1,237,063,156.75 RMB, compared to 760,042,162.51 RMB at the end of 2020[13] - Total liabilities as of the end of the third quarter of 2021 amounted to ¥1,388,193,843.40, significantly higher than ¥883,657,479.78 at the end of the third quarter of 2020[17] - Total current assets as of the end of the reporting period were CNY 1,182,910,934.76, slightly down from CNY 1,182,686,692.14 at the beginning of the year[23] - Total liabilities decreased to $883,657,479.78 from $951,093,100.06, representing a reduction of about 7%[24] - Non-current liabilities decreased significantly from $176,785,397.88 to $123,615,317.27, a drop of around 30%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,231[8] - The largest shareholder, Feng Yuxia, holds 89,702,855 shares, representing 23.57% of the total shares[9] - Total equity attributable to shareholders of the parent company reached ¥6,815,318,386.55, compared to ¥1,224,899,092.29 in the previous year[17] Business Growth and Orders - The increase in revenue and net profit was primarily driven by business growth and interest income from raised funds[6] - The company has secured over 3 billion RMB in orders as of the end of the reporting period, reflecting a year-on-year increase of over 70% in new orders[10] Research and Development - Research and development expenses for the third quarter of 2021 were ¥35,019,894.79, a decrease from ¥48,885,489.44 in the same period of 2020[17] Accounting and Financial Reporting - The company has implemented revised accounting standards for leases effective January 1, 2021, impacting financial reporting[26]
昭衍新药(603127) - 2021 Q3 - 季度财报